Schering-Plough Posts Golimumab Data
16th Nov 2005, 16:35 GMT
Drug maker Schering-Plough and J&J biotech unit Centocor said their rheumatoid arthritis treatment golimumab reached the primary endpoint of symptom reduction in a mid-stage clinical trial.
Schering-Plough Posts Golimumab Data related news:
- Centocor and Schering-Plough drug shows promise in RA — Pharmaceutical Business Review Online
- Schering-Plough Licenses Technology — StratWire - Business of Healthcare NewsFeed
- Merck/Schering-Plough Announces Update for the IMPROVE-IT Trial — Pharmaceuticals News from StratCenter.com
- Schering-Plough and Oncomethylome collaborate against brain cancer — Pharmaceutical Business Review Online
- Schering-Plough to Webcast Presentation at Credit Suisse 1st Boston Annual Health Care Conference — Operations-Related News from StratCenter.com
- Centocor: Centocor and Schering-Plough Next-Generation Biologic Shows Promise in the Treatment of Rheumatoid Arthritis in Phase 2 Trial — Market Wire - Pharmaceuticals and Biotech
- Centocor & Schering-Plough next generation biologic promising in phase 2 rheumatoid arthritis trial — EurekAlert! - Technology, Engineering and Computer Science
- Pfizer's Lipitor Data Favors Schering-Plough, Merck — Forbes.com Market News
- Positive phase I trial for Schering-Plough HCV treatment — Pharmaceutical Business Review Online
- Schering-Plough to Webcast Presentation at Credit Suisse First Boston Annual Health Care Conference — PR Newswire: All Releases
Latest news from Operations-Related News from StratCenter.com:
- Senior Housing Properties Trust Announces Proposed Public Offering of 5 mln Common Shares
- King Not Loving Its Shareholders
- Sepracor says asthma drug data is favorable
- Sepracor Presents Data on Asthma Drug
- Dr Reddy's Registers to List Shares
- PolyMedica Corp CEO to Ring the NASDAQ Stock Market Opening Bell
- Biovail to Present at the CSFB 2006 Healthcare Conference
- Genelabs reports lower Q3 loss
- Solexa posts narrowed Q3 loss
- Abbott's Humira Positive in 2 Studies